Mesoblast Ltd (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Ltd (ASX: MSB)
Latest News
Earnings Results
Mesoblast share price slumps as FY24 earnings fail to impress
Healthcare Shares
2 ASX healthcare shares outperforming peers on positive company news
Share Fallers
Why Brainchip, Gold Road, Mesoblast, and Telix shares are tumbling today
Share Fallers
Why Argosy Minerals, Flight Centre, Mesoblast, and Telix shares are sinking today
Healthcare Shares
Up 308% in 6 months, why is the Mesoblast share price tumbling today?
Share Fallers
Why Clinuvel, Mesoblast, Red Hill, and Resimac shares are sinking today
Healthcare Shares
What's going on with the Mesoblast share price today?
Share Market News
Top 10 most traded ASX shares and US stocks in May
Share Market News
Why these 3 top ASX 300 stocks dragged the benchmark lower this week
Healthcare Shares
Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?
Share Gainers
If you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much you'd have now!
Broker Notes
9 ASX All Ords shares elevated to 'strong buy' status in April
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Mesoblast Ltd
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
MSB Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 Dec 2024 | $2.42 | $-0.63 | -20.66% | 34,450,998 | $2.65 | $2.75 | $2.37 |
19 Dec 2024 | $3.05 | $1.07 | 54.04% | 46,747,972 | $2.36 | $3.09 | $2.35 |
18 Dec 2024 | $1.98 | $0.04 | 2.06% | 6,967,092 | $1.94 | $2.03 | $1.94 |
17 Dec 2024 | $1.94 | $0.11 | 6.01% | 7,999,348 | $1.88 | $1.96 | $1.84 |
16 Dec 2024 | $1.83 | $-0.01 | -0.54% | 6,269,896 | $1.80 | $1.90 | $1.80 |
13 Dec 2024 | $1.84 | $0.23 | 14.24% | 14,026,481 | $1.61 | $1.87 | $1.57 |
12 Dec 2024 | $1.62 | $-0.01 | -0.61% | 6,150,830 | $1.60 | $1.65 | $1.55 |
11 Dec 2024 | $1.63 | $-0.07 | -4.12% | 6,339,118 | $1.71 | $1.77 | $1.63 |
10 Dec 2024 | $1.70 | $0.04 | 2.42% | 6,644,655 | $1.70 | $1.75 | $1.69 |
09 Dec 2024 | $1.66 | $0.00 | 0.00% | 5,906,394 | $1.69 | $1.74 | $1.65 |
06 Dec 2024 | $1.66 | $-0.01 | -0.60% | 6,355,849 | $1.66 | $1.72 | $1.66 |
05 Dec 2024 | $1.67 | $-0.09 | -5.11% | 16,478,648 | $1.88 | $1.88 | $1.57 |
04 Dec 2024 | $1.76 | $-0.09 | -4.86% | 5,327,581 | $1.84 | $1.85 | $1.75 |
03 Dec 2024 | $1.85 | $0.05 | 2.78% | 9,045,086 | $1.81 | $1.87 | $1.73 |
02 Dec 2024 | $1.80 | $0.03 | 1.69% | 4,692,824 | $1.79 | $1.82 | $1.77 |
29 Nov 2024 | $1.77 | $0.03 | 1.72% | 2,353,723 | $1.75 | $1.79 | $1.73 |
28 Nov 2024 | $1.74 | $-0.02 | -1.14% | 4,655,494 | $1.78 | $1.82 | $1.74 |
27 Nov 2024 | $1.76 | $0.05 | 2.93% | 4,497,278 | $1.70 | $1.79 | $1.69 |
26 Nov 2024 | $1.71 | $0.03 | 1.79% | 5,206,356 | $1.74 | $1.75 | $1.64 |
25 Nov 2024 | $1.68 | $0.18 | 11.96% | 7,162,740 | $1.52 | $1.68 | $1.50 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
09 Jul 2024 | Philip Krause | Issued | 985,000 | $1,078,575 |
Issue of options.
|
08 May 2024 | Eric Rose | Buy | 19,734 | $151,207 |
On-market trade. US$
|
30 Apr 2024 | Eric Rose | Buy | 21,428 | $142,318 |
On-market trade. US$ ADS
|
12 Apr 2024 | Jane Bell | Buy | 233,918 | $199,999 |
On-market trade.
|
10 Jan 2024 | Joseph Swedish | Issued | 827,077 | $235,716 |
Issue of options.
|
10 Jan 2024 | Philip Facchina | Issued | 290,432 | $82,773 |
Issue of options.
|
10 Jan 2024 | Jane Bell | Issued | 326,729 | $93,117 |
Issue of options.
|
10 Jan 2024 | William (Bill) Burns | Issued | 409,651 | $116,750 |
Issue of options.
|
10 Jan 2024 | Silviu Itescu | Issued | 3,693,070 | $1,052,524 |
Issue of options.
|
10 Jan 2024 | Eric Rose | Issued | 1,960,765 | $558,818 |
Issue of options.
|
29 Dec 2023 | Joseph Swedish | Buy | 850 | $917 |
On-market trade. US$
|
28 Dec 2023 | Philip Krause | Buy | 37,500 | $41,536 |
On-market trade. US$
|
28 Dec 2023 | Joseph Swedish | Buy | 91,035 | $99,082 |
On-market trade. US$
|
28 Dec 2023 | William (Bill) Burns | Issued | 21,250 | $6,375 |
Rights issue.
|
28 Dec 2023 | Jane Bell | Issued | 61,905 | $18,571 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Professor Silviu Itescu | Chief Executive OfficerExecutive Director | Jun 2004 |
Dr. Itescu, prior to founding Mesoblast in 2004, Dr. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. Itescu has consulted for international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies.
|
Dr Eric A Rose | Non-Executive Director | Apr 2013 |
Dr. Rose is a physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon-in-Chief of Columbia Presbyterian Medical Center in New York. During this time his leadership of the NIH supported program Randomized Evaluation of Mechanical Circulatory Support in Heart Failure (REMATCH) resulted in the first FDA approval of an implantable left ventricular assist device for long term circulatory support, spawning an entire new industry. From 2007-2011, Dr. Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and emerging diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he oversaw development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr. Rose played a role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). Dr. Rose's tenure on the ABIOMED board ended in December 2022 with the sale of the company to Johnson & Johnson for $17.7 billion. Former directorships of listed public companies within the last 3 years: Chairman, SIGA Technologies, Inc. (2017 - 2021), Non-executive Director, ABIOMED, Inc. which was acquired by Johnson & Johnson. (2007 - 2012, 2014 - 2022
|
Mr William (Bill) A Burns | Non-Executive DirectorVice-Chairman | Mar 2014 |
Mr. Burns spent his entire management career at the Beecham Group and F. Hoffmann-La Roche Ltd. Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non-Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016. Mr Burns is also a member of the Oncology Advisory Board of the Universities of Cologne/ Bonn in Germany. In 2014, he was appointed a trustee of the Institute of Cancer Research(ICR), London, and in 2016 a Governor of The Wellcome Trust in London, UK. Mr Burns completed his terms of office at both ICR and Wellcome Trust and has retired from both positions.
|
Ms Jane Catherine Bell | Non-Executive Director | Aug 2022 |
Ms. Bell AM has 30 years of experience as a banking and finance lawyer with law firms, financial services and corporate treasury operations in the United States, Canada, Australia and the United Kingdom. She is an experienced Chair and non-executive Director in regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. Ms. Bell currently serves as Deputy Chair of Monash Health, Australia's public health service delivering more than 3.46 million episodes of care, and Chair of its Audit Committee. She is also a director of publicly-listed biotechnology company Amplia Therapeutics and Chair of its Audit Committee and of Jessie McPherson Private Hospital. She is a former Chair of Royal Melbourne Hospital and former Chair of Biomedical Research Victoria as well as of Advisory Groups for the Royal Australian and New Zealand College of Obstetricians and Melbourne Genomics Health Alliance, a former director of Hudson Institute of Medical Research and Chair of its Intellectual Property and Commercialization Committee and director of U Ethical, Australia's first ethical funds manager. Other current directorships of listed public companies: Non-Executive Director, Amplia Therapeutics Limited (since 2021). She is member of Risk Committee.
|
Mr Philip J. Facchina | Non-Executive Director | Mar 2021 |
Mr. Facchina brings more than 35 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter, overseeing the company's strategic relationships, including its relationships with the broad US ambulatory surgical center (ASC) market and its constituents. Prior to SurgCenter, Mr. Facchina spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take-privates. From 2008 to 2017, Mr. Facchina served as a Partner, Co-Portfolio Manager and the Chief Operating Officer of Ramsey Asset Management, an institutional investment management firm, and from 1998 to 2008 Mr. Facchina led the technology, media, and communications and healthcare investment banking groups of FBR Capital Markets. Mr. Facchina currently serves as an independent director for ViON Corporation and MilltechFX, and is Advisor to the CEO of Johanna Foods Inc, where he chairs the Audit Committee. Previously, among other directorships and committee posts, Mr. Facchina served on the Board of Web.com (Nasdaq: WEB), where he led Corporate Governance. He is member of Risk Committee.
|
Dr Philip R Krause | Non-Executive Director | Mar 2022 |
Dr Krause, with over 30 years of experience at the Food and Drug Administration, Dr. Krause has a combination of scientific, regulatory, clinical, and public health experience. He is a physician with board certification in internal medicine and infectious diseases and a researcher with over 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development. He recently served as deputy director of FDA's Office of Vaccines Research and Review, where he led assessments of biological products for evaluation and licensure and helped to oversee the development and evaluation of all vaccines authorized and licensed in the US from 2011-2021. Dr Krause has a strategic advisory consulting role with Mesoblast, providing advice on regulatory strategies.
|
Ms Niva Sivakumar | Joint Company Secretary | Oct 2019 |
-
|
Mr Paul Hughes | Joint Company Secretary | Apr 2022 |
-
|
Andrew Chaponnel, | Chief Financial Officer |
-
|
|
Peter Howard | Group General Counsel and Corporate Executive |
-
|
|
Justin Horst | Head of Manufacturing |
-
|
|
Geraldine Storton | Head of Regulatory Affairs and Quality Management |
-
|
|
Niva Sivakumar | Joint Company Secretary |
-
|
|
Paul Hughes | Joint Company Secretary |
-
|
|
Michael Schuster | Pharma Partnering |
-
|
|
Paul Simmons | Scientific Advisor to the Chief Executive Officer |
-
|
|
Fiona Se | SVP and Head Translational Research |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
J P Morgan Nominees Australia Pty Limited | 372,563,409 | 32.63% |
HSBC Custody Nominees (Australia) Limited | 127,511,937 | 11.17% |
Citicorp Nominees Pty Limited | 73,041,006 | 6.40% |
Professor Silviu Itescu | 67,751,838 | 5.93% |
UBS Nominees Pty Ltd | 14,630,688 | 1.28% |
Thorney Holdings Pty Ltd | 10,000,000 | 0.88% |
Tiga Trading Pty Ltd | 10,000,000 | 0.88% |
BNP Paribas Noms Pty Ltd | 9,515,494 | 0.83% |
Josaka Investments Pty Ltd | 8,821,137 | 0.77% |
Independent Asset Management Pty Limited | 6,715,891 | 0.59% |
Merrill Lynch (Australia) Nominees Pty Limited | 5,684,853 | 0.50% |
HSBC Custody Nominees (Australia) Limited i | 5,301,000 | 0.46% |
BNP Paribas Nominees Pty Ltd | 5,011,552 | 0.44% |
BNP Paribas Nominees Pty Ltd i | 4,086,170 | 0.36% |
Mr Gregory John Matthews & Mrs Janine Marie Matthews | 3,141,063 | 0.28% |
National Nominees Limited | 2,856,026 | 0.25% |
Finclear Services Pty Ltd | 2,729,106 | 0.24% |
Citicorp Nominees Pty Limited i | 2,502,195 | 0.22% |
Tamit Nominees Pty Ltd | 2,380,953 | 0.21% |
Mann Securities Pty Ltd | 2,352,942 | 0.21% |
Lavya Pty Ltd | 2,000,166 | 0.18% |